China-Origin Drug Licensing Set to Surge Again as Pipeline Draws Global Buyers
Global pharmaceutical companies are accelerating purchases of China-developed experimental medicines as they aim to cut costs ahead of looming patent expirations. Licensing deal values tied to the greater China region jumped to an unprecedented $137.7 billion last year, and industry advisers say the total could grow substantially again over the nex…